Radiation therapy-associated toxicity: Etiology, management, and prevention
- PMID: 34255347
- DOI: 10.3322/caac.21689
Radiation therapy-associated toxicity: Etiology, management, and prevention
Abstract
Radiation therapy (RT) is a curative treatment for many malignancies and provides effective palliation in patients with tumor-related symptoms. However, the biophysical effects of RT are not specific to tumor cells and may produce toxicity due to exposure of surrounding organs and tissues. In this article, the authors review the clinical context, pathophysiology, risk factors, presentation, and management of RT side effects in each human organ system. Ionizing radiation works by producing DNA damage leading to tumor death, but effects on normal tissue may result in acute and/or late toxicity. The manifestation of toxicity depends on both cellular characteristics and affected organs' anatomy and physiology. There is usually a direct relationship between the radiation dose and volume to normal tissues and the risk of toxicity, which has led to guidelines and recommended dose limits for most tissues. Side effects are multifactorial, with contributions from baseline patient characteristics and other oncologic treatments. Technological advances in recent decades have decreased RT toxicity by dramatically improving the ability to deliver RT that maximizes tumor dose and minimizes organ dose. Thus the study of RT-associated toxicity is a complex, core component of radiation oncology training that continues to evolve alongside advances in cancer management. Because RT is used in up to one-half of all patients with cancer, an understanding of its acute and late effects in different organ systems is clinically pertinent to both oncologists and nononcologists.
Keywords: quality of life; radiation; side effects; toxicity.
© 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
Similar articles
-
Supportive care for toxicities in children undergoing radiation therapy.Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28597. doi: 10.1002/pbc.28597. Pediatr Blood Cancer. 2021. PMID: 33818886 Review.
-
Palliative radiation oncology in pediatric patients.Ann Palliat Med. 2019 Jul;8(3):285-292. doi: 10.21037/apm.2019.05.01. Epub 2019 May 27. Ann Palliat Med. 2019. PMID: 31280578 Review.
-
Radiation therapy-related toxicity (including pneumonitis and fibrosis).Emerg Med Clin North Am. 2009 May;27(2):293-310. doi: 10.1016/j.emc.2009.01.010. Emerg Med Clin North Am. 2009. PMID: 19447313
-
Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.Eur Urol. 2019 Mar;75(3):464-476. doi: 10.1016/j.eururo.2018.12.003. Epub 2018 Dec 17. Eur Urol. 2019. PMID: 30573316
-
Patient-reported symptoms during radiotherapy : Clinically relevant symptom burden in patients treated with palliative and curative intent.Strahlenther Onkol. 2017 Jul;193(7):570-577. doi: 10.1007/s00066-017-1146-5. Epub 2017 Jun 1. Strahlenther Onkol. 2017. PMID: 28573475 English.
Cited by
-
Predictive Factors for Chemoradiation-Induced Oral Mucositis and Dysphagia in Head and Neck Cancer: A Scoping Review.Cancers (Basel). 2023 Dec 4;15(23):5705. doi: 10.3390/cancers15235705. Cancers (Basel). 2023. PMID: 38067408 Free PMC article. Review.
-
Nanogels as target drug delivery systems in cancer therapy: A review of the last decade.Front Pharmacol. 2022 Sep 8;13:874510. doi: 10.3389/fphar.2022.874510. eCollection 2022. Front Pharmacol. 2022. PMID: 36160424 Free PMC article.
-
UBA1 inhibition contributes radiosensitization of glioblastoma cells via blocking DNA damage repair.Front Pharmacol. 2023 Mar 7;14:1073929. doi: 10.3389/fphar.2023.1073929. eCollection 2023. Front Pharmacol. 2023. PMID: 36959858 Free PMC article.
-
Exploring Natural Products as Radioprotective Agents for Cancer Therapy: Mechanisms, Challenges, and Opportunities.Cancers (Basel). 2023 Jul 12;15(14):3585. doi: 10.3390/cancers15143585. Cancers (Basel). 2023. PMID: 37509245 Free PMC article. Review.
-
Application of Diffusion Kurtosis Imaging in Evaluating Acute Xerostomia in Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy.Front Oncol. 2022 May 19;12:870315. doi: 10.3389/fonc.2022.870315. eCollection 2022. Front Oncol. 2022. PMID: 35664750 Free PMC article.
References
-
- Royce TJ, Qureshi MM, Truong MT. Radiotherapy utilization and fractionation patterns during the first course of cancer treatment in the United States from 2004 to 2014. J Am Coll Radiol. 2018;15:1558-1564.
-
- Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129-1137.
-
- Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 suppl):S10-S19.
-
- Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
-
- Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56-73.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources